查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2102838

內視鏡黏膜下剝離術（ESD）市場 - 全球預測，2026-2032年

Endoscopic Submucosal Dissection Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，內視鏡黏膜下剝離術 (ESD) 市場將成長至 6.6251 億美元，複合年成長率為 6.13%。

主要市場統計數據
基準年 2025 4.3664億美元
預計年份：2026年 4.6184億美元
預測年份 2032 6.6251億美元
複合年成長率 (%) 6.13%

內視鏡黏膜下剝離術（ESD）是一種先進的保留器官的內視鏡切除術，用於將某些表淺胃腸道腫瘤作為一個整體切除。這使得術中能夠進行精確的組織病理學檢查和切緣評估，並有望實現無需傳統手術的根治性治療。全球可進行ESD評估的病變數量龐大，進一步凸顯了其臨床意義。 2022年，全球報告了1,926,425例新發結直腸癌、968,784例新發胃癌和511,054例新發食道癌。目前的臨床指引建議ESD作為許多淺層食道鱗狀上皮病變和胃病變的一線治療方法，並推薦其作為結直腸（尤其是直腸）病變（提示黏膜下浸潤範圍有限）的選擇性整塊切除策略。

對於相關人員，ESD 的現狀與其說是取決於該手術本身的廣泛採用，不如說是取決於早期癌症檢測、高解析度內視鏡成像、專家培訓、病理檢測系統、麻醉支援和多學科決策的整合。

永續發展教育現況的變革性變化

目前，內視鏡黏膜下剝離術（ESD）的發展趨勢正從廣泛應用轉向整合早期癌症治療路徑。 ESD在臨床指引中的重要性日益凸顯，因為它能夠實現整塊切除和精準分期，即使在那些碎片化切除可能導致病理診斷不完整的病變中也是如此。另一方面，在根治性ESD術後的後續觀察路徑中，高解析度白光內視鏡和染色內視鏡在低風險切除病例中正逐漸取代基於截面的傳統分期方法，受到越來越多的重視。

人工智慧對永續發展教育（ESD）的累積影響

人工智慧 (AI) 正透過提高對病變的檢出率和特徵分析能力，間接且累積改變著內視鏡黏膜下剝離術 (ESD) 的發展，使患者能夠更早地轉診至更高級的切除術。一項關於 AI 輔助大腸鏡檢查的隨機試驗統合分析顯示，與標準大腸鏡檢查相比，電腦輔助檢測 (CAD) 的腺瘤檢出率更高，分別為 41.4% 和 33.0%，相對風險為 1.26。這對 ESD 具有重要意義，因為更準確地識別扁平病變、非息肉樣病變、瘢痕性病變、側向浸潤性病變或可疑病變，可以提高適應症的準確性，並減少不恰當的、碎片化的治療。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

由於亞太地區人口大規模，早期胃癌、大腸直腸癌和食道癌病例集中，且內視鏡醫療環境成熟，因此該地區仍是內視鏡黏膜下剝離術（ESD）臨床應用最廣泛的地區。 2022年，中國報告了517,106例大腸癌、358,672例胃癌和224,012例食道癌。同時，日本報告了145,756例大腸直腸癌和126,724例胃癌，而韓國的大腸直腸癌和胃癌則位列前三名。印度的癌症負擔有所不同，2022 年食道癌病例 70,637 例，大腸直腸癌病例 70,038 例，胃癌病例 64,611 例。這些趨勢使得亞太地區成為高品質病變檢測、胃 ESD、結直腸 ESD、食道 ESD 和系統化高級內視鏡訓練的優先區域。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協地區ESD的應用前景十分廣闊，但其面臨的挑戰包括篩檢率不均、內視鏡檢查能力參差不齊以及對上消化道和結直腸疾病診斷的需求日益成長。東南亞地區的醫療衛生系統可以透過將國家癌症控制計畫與轉診醫療機構對接，改善醫療服務的可近性，尤其是在胃癌發病率仍然較高的地區，例如越南，該國2022年報告了16277例胃癌病例。在東協地區，最有效的策略可能是結合提高診斷品質、專家指導、規範病變記錄以及舉辦區域病例研討會等措施，而不是立即嘗試大規模推廣ESD。

關鍵國家對與ESD相關的主要醫療保健系統的洞察

在北美，美國為內視鏡黏膜下剝離術（ESD）的引入提供了絕佳的機會。這是因為2022年，大腸直腸癌在該國癌症發生率居前列，病例達160,186例，胃癌和食道癌的病例也分別達到25,554例和18,747例。加拿大的情況與之類似，但規模較小，報告的大腸癌病例為23,725例，胃癌病例為4,113例，食道癌病例為3,136例。墨西哥報告的大腸直腸癌病例為16,082例，胃癌病例為9,516例，反映了各國在醫療資源可近性上的差異。因此，建立轉診中心和早期發現病變對於ESD的安全推廣至關重要。

為行業領導者提供的實用建議

產業領導者應優先建構以臨床主導的內視鏡黏膜下剝離術（ESD）生態系統，而非僅擴大孤立的手術範圍。首先，應建立轉診途徑，以便在碎片化切除影響病理診斷之前，識別適合整塊切除的病變。其次，應支援基於能力的培訓，包括光學診斷、模擬屍檢、監督操作、出血和穿孔處理、檢體定位以及後續觀察計劃。第三，應將數位化文件和人工智慧輔助檢測與臨床管治結合，使人工智慧能夠在不影響人為責任的前提下，提高病變識別和分診的準確性。第四，應投資建立結果登記系統，追蹤整塊切除、R0切除、根治根治性切除、復發、不利事件、手術時間、再次手術的需求。第五，應將區域策略重點放在疾病負擔沉重的國家和能夠確保早期診斷、病​​理、麻醉和補救手術有效協調的專科中心。這些建議與已發布的指南一致，指南強調ESD適用於特定的淺層胃腸道病變，並指出培訓仍然是臨床實踐的主要障礙。

調查方法

本執行摘要採用結構化的證據整合方法編寫，並專注檢驗的臨床和流行病學資訊來源。分析優先考慮了關於內視鏡黏膜下剝離術（ESD）適應症和根治性切除標準的國際臨床指南、經同行評審的人工智慧輔助內視鏡系統評價，以及來自權威癌症資料庫的人群癌症發病率、死亡率和盛行率數據。由於大腸直腸癌、胃癌和食道癌的疾病負擔與內視鏡黏膜下剝離術（ESD）的臨床選擇過程最為檢驗相關，因此，本文將國家和地區層面的分析結果與2022年結直腸癌、胃癌和食道癌的癌症負擔預測值進行了比對。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 內視鏡黏膜下剝離術（ESD）市場：依產品分類

  • 內視鏡
    • 大腸鏡檢查
    • 十二指腸內視鏡檢查
    • 胃鏡檢查
  • ESD刀
    • 雙刀
    • IT刀
    • 鉤刀
    • 針刀
  • 針頭
  • 止血裝置
    • 凝血鉗
    • 止血鉗
  • 組織牽引裝置
  • 包含的設備
    • 帽子
    • 供氣設備
    • 套管針

第8章 內視鏡黏膜下剝離術 (ESD) 市場：依手術類型分類

  • 全層切除
  • 混合型靜電放電
  • 部分厚度切除

第9章 內視鏡黏膜下剝離術（ESD）市場：依適應症類型分類

  • 結腸癌
  • 食道癌
  • 胃癌
  • 癌前病變

第10章 內視鏡黏膜下剝離術（ESD）市場：依疾病階段分類

  • 良性腫瘤
  • 惡性腫瘤
    • 入侵
    • 非侵入性

第11章 內視鏡黏膜下剝離術 (ESD) 市場：依最終使用者類型分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 內視鏡黏膜下剝離術（ESD）市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 中東
  • 非洲

第13章 內視鏡黏膜下剝離術 (ESD) 市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 內視鏡黏膜下剝離術（ESD）市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 德國
  • 韓國
  • 印度
  • 法國
  • 英國
  • 義大利
  • 加拿大
  • 巴西
  • 澳洲
  • 墨西哥
  • 俄羅斯
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Olympus Corporation
  • Fujifilm Holdings Corporation
  • Boston Scientific Corporation
  • Erbe Elektromedizin GmbH
  • PENTAX Medical by Hoya Corporation
  • MICRO-TECH（Nanjing）Co., Ltd.
  • Medtronic PLC
  • Cook Group Incorporated
  • Sumitomo Bakelite Co., Ltd.
  • ConMed Corporation
  • Karl Storz SE & Co. KG
  • Ovesco Endoscope AG
  • STERIS plc
  • Hangzhou AGS MedTech Co., Ltd.
  • Medi-Globe GmbH by DCC Healthcare
  • Aohua Endoscopy Co., Ltd.
  • Anrei Medical（Hangzhou）Co., Ltd.
  • Leo Medical Co. Ltd.
  • Seikagaku Corporation
  • Creo Medical Group plc
  • Jiangsu Vedkang Medical Science and Technology Co., Ltd.
  • MTW-Endoskopie W. Haag KG
  • Cosmo Pharmaceuticals NV
  • GI Supply, Inc.
  • Zeon Medical Co., Ltd.
  • Endo-Flex GmbH by Medi-Globe Group
  • Lumendi AG
  • Upexmed Co., Ltd.
  • Actuated Medical, Inc.
  • Agilis Robotics Limited
  • Ambu A/S
  • ATRACT Device & Co.
  • Beijing ZKSK Technology Co., Ltd.
  • Flexicare Medical Ltd.
  • Interscope, Inc.
  • Kachu Technology Co., Ltd.
  • Neptune Medical Inc.
  • Richard Wolf GmbH
  • Sunarrow Co., Ltd.
  • TOP Corporation
  • Zhejiang Soudon Medical Technology Co., Ltd.
Product Code: MRR-F611BFBC6402

The Endoscopic Submucosal Dissection Market is projected to grow by USD 662.51 million at a CAGR of 6.13% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 436.64 million
Estimated Year [2026] USD 461.84 million
Forecast Year [2032] USD 662.51 million
CAGR (%) 6.13%

Endoscopic submucosal dissection is an advanced, organ-preserving endoscopic resection technique used to remove selected superficial gastrointestinal neoplasia in one piece, enabling precise histopathology, margin assessment, and potentially curative treatment without conventional surgery. The clinical relevance is reinforced by the global burden of lesions that may enter an ESD evaluation pathway: in 2022, colorectal cancer accounted for 1,926,425 new cases worldwide, stomach cancer for 968,784, and oesophageal cancer for 511,054. Current clinical guidance supports ESD as a first-option approach for many superficial esophageal squamous and gastric lesions and as a selective en bloc strategy for colorectal, particularly rectal, lesions with features suggesting limited submucosal invasion.

For industry stakeholders, the ESD landscape is defined less by broad procedural availability and more by the convergence of early cancer detection, high-definition endoscopic imaging, expert training, pathology readiness, anesthesia support, and multidisciplinary decision-making.

Transformative Shifts in the ESD Landscape

The ESD landscape is shifting from procedure-centric adoption toward integrated early-cancer pathways. Clinical guidance has elevated ESD because it can deliver en bloc resection and accurate staging in lesions where piecemeal removal risks incomplete pathology, while surveillance pathways after curative ESD increasingly rely on high-definition white-light endoscopy and chromoendoscopy rather than routine cross-sectional staging for low-risk resections.

A second transformation is the move from opportunistic expertise to structured competency development. International survey evidence shows that real-world ESD training remains constrained by time and access: limited training time was rated a major barrier by 55.3% of respondents in Asia-Pacific, 48.6% in Southeast Europe, 41.7% in Africa and the Middle East, 36.0% in the Americas, and 21.0% in Northwest Europe. This underlines a central operational shift: successful ESD programs require protected training, supervised progression, simulation, complication management, referral triage, and outcomes documentation.

A third shift is lesion-selection discipline. ESD is gaining strategic importance where clinicians must balance curative intent, accurate staging, recurrence prevention, patient preference, and surgical avoidance. The strongest adopters are building pathways that connect screening, optical diagnosis, lesion mapping, resection planning, specimen handling, pathology review, and surveillance in a single quality framework.

Cumulative Impact of Artificial Intelligence in ESD

Artificial intelligence is reshaping ESD indirectly and cumulatively by improving the upstream detection and characterization of lesions that may be referred for advanced resection. In randomized-trial meta-analysis of AI-assisted colonoscopy, the pooled adenoma detection rate was higher with computer-aided detection than standard colonoscopy, at 41.4% versus 33.0%, with a relative risk of 1.26. This matters for ESD because better identification of flat, nonpolypoid, scarred, laterally spreading, or suspicious lesions can improve referral quality and reduce inappropriate piecemeal treatment.

AI is also moving into upper-GI decision support. Systematic review evidence in early upper gastrointestinal cancer reported pooled patient-based performance for AI-assisted diagnosis with an AUC of 0.95, sensitivity of 0.95, and specificity of 0.82, while gastric-focused reviews describe applications in early lesion detection, invasion-depth assessment, margin delineation, classification, and segmentation. These capabilities support the ESD workflow by strengthening pre-resection risk stratification, video documentation, training feedback, and multidisciplinary review, though they do not replace expert optical diagnosis, pathology, or operator competency.

The cumulative impact is a more data-rich ESD ecosystem: AI can expand the pool of detected lesions, standardize quality indicators, support remote case review, and help training programs analyze procedural video. The key leadership challenge is governance, including validating algorithms locally, preventing over-referral of clinically insignificant findings, maintaining human accountability, and aligning AI outputs with guideline-based ESD indications.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the most clinically influential region for endoscopic submucosal dissection because the burden of early gastric, colorectal, and esophageal neoplasia is concentrated across large populations and mature endoscopy ecosystems. China reported 517,106 colorectal, 358,672 stomach, and 224,012 oesophageal cancer cases in 2022, while Japan reported 145,756 colorectal and 126,724 stomach cancer cases, and South Korea reported colorectal and stomach cancers among its top three cancer sites. India adds a different burden profile, with oesophageal cancer at 70,637 cases, colorectal cancer at 70,038, and stomach cancer at 64,611 in 2022. These patterns make Asia-Pacific a priority for high-quality lesion detection, gastric ESD, colorectal ESD, esophageal ESD, and structured advanced endoscopy training.

North America is characterized by strong colorectal cancer screening infrastructure and growing interest in organ-preserving advanced resection. The United States recorded 160,186 colorectal cancer cases in 2022, with stomach and oesophageal cancers at 25,554 and 18,747, respectively; Canada recorded 23,725 colorectal cancer cases, with stomach and oesophageal cancers at 4,113 and 3,136. The region's ESD priorities center on expert-center access, payer-aligned referral pathways, North American guideline adoption, and training models that help transition appropriate lesions from surgery or piecemeal endoscopic mucosal resection to en bloc ESD where clinically justified.

Latin America shows rising relevance for ESD through concentrated colorectal and upper-GI disease in major referral systems. Brazil reported 60,118 colorectal, 23,021 stomach, and 10,985 oesophageal cancer cases in 2022, while Mexico reported 16,082 colorectal, 9,516 stomach, and 1,433 oesophageal cancer cases. The region's near-term opportunity lies in centralizing complex ESD cases, improving early diagnosis, strengthening pathology turnaround, and building bilingual or regional training networks that allow advanced endoscopists to progress safely.

Europe combines high colorectal burden, guideline-driven practice, and strong cross-border clinical education. The United Kingdom, Germany, France, Russia, Italy, and Spain each reported substantial colorectal cancer case counts in 2022, with 49,429, 62,544, 51,636, 83,693, 54,784, and 39,421 cases, respectively, making colorectal ESD, rectal ESD, and advanced lesion triage central themes. European guidance supports ESD for selected superficial GI lesions and provides a foundation for harmonized quality measures, surveillance, and training.

The Middle East is developing as a selective, tertiary-care ESD environment where advanced endoscopy programs must align specialist availability with upper-GI cancer risk, anesthesia capacity, and pathology support. Regional planning is strengthened by the fact that neighboring West Asian disease patterns include high stomach cancer relevance, with Iran listed among the countries with the highest stomach cancer incidence in 2022. For Middle Eastern health systems, ESD readiness depends on referral governance, complication rescue capability, and physician training rather than simple equipment availability.

Africa's ESD trajectory is closely linked to early detection capacity. Oesophageal cancer incidence has been reported as particularly high in Eastern and Southern Africa, yet ESD can only deliver its full clinical value when lesions are identified while still superficial. Training constraints are material: Africa and the Middle East together reported limited available training time as a major barrier in 41.7% of survey responses. The region's priority is therefore a stepwise pathway from diagnostic endoscopy access and pathology infrastructure to regional centers of excellence capable of safe ESD.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN represents a heterogeneous ESD opportunity shaped by uneven screening coverage, variable endoscopy capacity, and growing upper-GI and colorectal diagnostic needs. Southeast Asian systems can improve access by linking national cancer-control programs to referral centers, particularly where gastric cancer remains visible in regional data, such as Vietnam's 16,277 stomach cancer cases in 2022. The most effective ASEAN strategy is likely to combine diagnostic quality improvement, expert mentoring, standardized lesion documentation, and regional case conferences rather than attempting immediate broad-based ESD diffusion.

GCC health systems are positioned to adopt ESD through tertiary hospitals, multidisciplinary oncology programs, and high-acuity endoscopy services. The strategic focus should be on guideline-based lesion selection, physician credentialing, adverse-event response, and integration with pathology and surgical backup. Because ESD is highly skill dependent, GCC leaders should emphasize durable training partnerships, simulation, and outcomes registries before expanding case volumes.

The European Union benefits from guideline alignment, colorectal screening maturity, and dense specialist networks, making it a natural environment for standardized ESD quality indicators. Germany, France, Italy, and Spain together show large colorectal cancer burdens, while European guidance supports ESD for selected superficial esophageal, gastric, Barrett's-associated, and colorectal lesions. EU priorities include interoperable training curricula, cross-border referral pathways for complex cases, and evidence-based surveillance after curative resection.

BRICS and expanded BRICS economies create one of the largest clinically relevant ESD platforms because the grouping includes countries with major absolute burdens of colorectal, stomach, and oesophageal cancer. Official BRICS information lists the original members with newer members admitted in 2024-2025, including Egypt, Ethiopia, Indonesia, Iran, Saudi Arabia, and the United Arab Emirates; within the original high-burden members, China, India, Brazil, and Russia alone show substantial ESD-relevant case loads across colorectal and upper-GI cancers.

G7 countries combine advanced endoscopy infrastructure with large ageing populations and high diagnostic intensity. The United States, Canada, Japan, the United Kingdom, Germany, France, and Italy all show meaningful colorectal cancer burdens, while Japan's stomach cancer burden remains especially important for gastric ESD expertise. G7 priorities include competency-based training, AI-enabled detection governance, appropriate reimbursement logic, and consistent reporting of en bloc, R0, curative resection, recurrence, and adverse events.

NATO is not a healthcare purchasing or clinical-governance bloc, but its overlap with North American and European health systems makes it relevant for resilience thinking, workforce mobility, training exchange, and hospital readiness. Since NATO's membership framework is political and security-oriented, ESD stakeholders should treat the grouping as a proxy for shared high-income infrastructure in many member states rather than as a direct clinical channel.

Key Country Insights Across Major ESD-Relevant Healthcare Systems

In North America, the United States is the anchor ESD opportunity because colorectal cancer ranked among the country's top cancers with 160,186 cases in 2022, while stomach and oesophageal cancers added 25,554 and 18,747 cases; Canada's profile is smaller but similar, with 23,725 colorectal, 4,113 stomach, and 3,136 oesophageal cases. Mexico adds a different access dynamic, reporting 16,082 colorectal and 9,516 stomach cancer cases, making referral-center development and early lesion recognition important for safe ESD expansion.

In Latin America, Brazil is the key country driver, with 60,118 colorectal, 23,021 stomach, and 10,985 oesophageal cancer cases in 2022. Its ESD priorities include concentrating expertise in advanced endoscopy centers, linking screening colonoscopy to lesion triage, and formalizing referral criteria so patients with superficial lesions are evaluated for organ-preserving resection before surgical escalation.

In Europe, the United Kingdom recorded 49,429 colorectal, 9,601 oesophageal, and 6,034 stomach cancer cases in 2022; Germany recorded 62,544 colorectal, 14,088 stomach, and 7,310 oesophageal cases; France recorded 51,636 colorectal, 7,673 stomach, and 4,942 oesophageal cases; Russia recorded 83,693 colorectal, 38,883 stomach, and 9,345 oesophageal cases; Italy recorded 54,784 colorectal and 13,501 stomach cases; and Spain recorded 39,421 colorectal and 7,173 stomach cases. These country profiles make colorectal ESD, rectal lesion management, and upper-GI expert pathways important across Western, Southern, and Eastern Europe.

In Asia-Pacific, China represents the largest absolute ESD-relevant burden, with 517,106 colorectal, 358,672 stomach, and 224,012 oesophageal cancer cases in 2022, while India reported 70,637 oesophageal, 70,038 colorectal, and 64,611 stomach cases. Japan remains central to gastric and colorectal ESD expertise, reporting 145,756 colorectal, 126,724 stomach, and 19,926 oesophageal cases; Australia's ESD relevance is led by colorectal cancer, with 17,088 cases and lower stomach and oesophageal counts of 2,837 and 1,755; and South Korea reported colorectal and stomach cancers as its second and third most frequent cancers, with 29,560 and 29,267 cases.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically governed ESD ecosystems rather than isolated procedural expansion. First, build referral pathways that identify lesions appropriate for en bloc resection before piecemeal removal compromises pathology. Second, support competency-based training that includes optical diagnosis, simulated dissection, supervised procedures, bleeding and perforation management, specimen orientation, and surveillance planning. Third, align digital documentation and AI-assisted detection with clinical governance so that AI improves lesion recognition and triage without weakening human accountability. Fourth, invest in outcomes registries that track en bloc resection, R0 resection, curative resection, recurrence, adverse events, procedure time, and need for additional surgery. Fifth, focus regional strategy on high-burden countries and expert centers where early diagnosis, pathology, anesthesia, and rescue surgery can be reliably coordinated. These recommendations align with published guidance emphasizing ESD for selected superficial GI lesions and with evidence that training capacity remains a major real-world barrier.

Research Methodology

This executive summary was developed using a structured evidence-synthesis approach focused on verified clinical and epidemiological sources. The analysis prioritized international clinical guidance for ESD indications and curative-resection criteria, peer-reviewed systematic reviews on AI-assisted endoscopy, and population-level cancer incidence, mortality, and prevalence data from recognized cancer registry-based sources. Country and regional insights were triangulated across 2022 cancer burden estimates for colorectal, stomach, and oesophageal cancers, because these disease areas most directly shape the clinical funnel for endoscopic submucosal dissection.

The methodology deliberately excludes market estimation, market sizing, market share, and forecasting. Instead, it evaluates burden of disease, guideline alignment, training constraints, procedural readiness, AI-enabled diagnostic shifts, and health-system infrastructure. Conclusion: ESD as a Core Capability in Organ-Preserving GI Cancer Care

Endoscopic submucosal dissection is becoming a defining capability in advanced therapeutic endoscopy because it connects early cancer detection with organ-preserving, pathology-rich treatment. Its adoption is strongest where screening, high-quality imaging, expert training, pathology, anesthesia, and multidisciplinary governance work together. Asia-Pacific leads through high upper-GI and colorectal disease burden and mature ESD expertise; North America and Europe are advancing through guidelines, colorectal screening, and expert-center models; Latin America, the Middle East, and Africa show meaningful opportunities where early detection and training infrastructure are strengthened.

The next phase of ESD will be shaped by disciplined lesion selection, structured training, AI-assisted detection, outcomes transparency, and regional referral networks. Leaders that focus on clinical quality, access, and evidence-based workflows will be best positioned to support safe, scalable, and patient-centered ESD adoption without relying on speculative commercial metrics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
      • 4.3.1.1. Earlier Lesion Detection Expands the Treatable Pool for Organ-Preserving Resection
      • 4.3.1.2. Organ-Preservation Economics Strengthen the Hospital Business Case
      • 4.3.1.3. Integrated Visualization and Therapeutic Tools Improve Procedural Confidence
      • 4.3.1.4. Guideline Support Converts Specialist Practice into Institutional Adoption
    • 4.3.2. Key Restraints
      • 4.3.2.1. Operator Scarcity Limits Conversion from Clinical Need to Procedure Volume
      • 4.3.2.2. Reimbursement and Procedure-Time Economics Pressure Hospital Adoption
    • 4.3.3. Key Opportunities
      • 4.3.3.1. Convert Fragmented Consumables into Indication-Specific ESD Kits
      • 4.3.3.2. Attach AI Workflow Software to Premium Endoscopy Platforms
      • 4.3.3.3. Use Traction and Robotic Assistance to Reduce Procedure Complexity
    • 4.3.4. Key Challenges
      • 4.3.4.1. Scale Clinical Capability Before Device Availability Outpaces Operator Readiness
      • 4.3.4.2. Navigate Regulated Regionalization Without Sacrificing Margin or Market Access
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endoscopic Submucosal Dissection Market, by Product

  • 7.1. Introduction
  • 7.2. Endoscopes
    • 7.2.1. Colonoscopes
    • 7.2.2. Duodenoscopes
    • 7.2.3. Gastroscopes
  • 7.3. ESD Knives
    • 7.3.1. Dual Knife
    • 7.3.2. IT Knife
    • 7.3.3. Hook Knife
    • 7.3.4. Needle Knife
  • 7.4. Injection Needles
  • 7.5. Hemostasis Devices
    • 7.5.1. Coagulation Forceps
    • 7.5.2. Hemostatic Forceps
  • 7.6. Tissue Retraction Devices
  • 7.7. Accessory Devices
    • 7.7.1. Cap & Hood
    • 7.7.2. Insufflations Units
    • 7.7.3. Trocars

8. Endoscopic Submucosal Dissection Market, by Procedure Type

  • 8.1. Introduction
  • 8.2. Full-Thickness Resection
  • 8.3. Hybrid ESD
  • 8.4. Partial-Thickness Resection

9. Endoscopic Submucosal Dissection Market, by Indication Type

  • 9.1. Introduction
  • 9.2. Colorectal Cancer
  • 9.3. Esophageal Cancer
  • 9.4. Gastric Cancer
  • 9.5. Precancerous Lesions

10. Endoscopic Submucosal Dissection Market, by Disease Condition

  • 10.1. Introduction
  • 10.2. Benign Tumors
  • 10.3. Malignant Tumors
    • 10.3.1. Invasive
    • 10.3.2. Non-Invasive

11. Endoscopic Submucosal Dissection Market, by End-User Type

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Endoscopic Submucosal Dissection Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Middle East
  • 12.6. Africa

13. Endoscopic Submucosal Dissection Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Endoscopic Submucosal Dissection Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. Germany
  • 14.5. South Korea
  • 14.6. India
  • 14.7. France
  • 14.8. United Kingdom
  • 14.9. Italy
  • 14.10. Canada
  • 14.11. Brazil
  • 14.12. Australia
  • 14.13. Mexico
  • 14.14. Russia
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Olympus Corporation
  • 16.2. Fujifilm Holdings Corporation
  • 16.3. Boston Scientific Corporation
  • 16.4. Erbe Elektromedizin GmbH
  • 16.5. PENTAX Medical by Hoya Corporation
  • 16.6. MICRO-TECH (Nanjing) Co., Ltd.
  • 16.7. Medtronic PLC
  • 16.8. Cook Group Incorporated
  • 16.9. Sumitomo Bakelite Co., Ltd.
  • 16.10. ConMed Corporation
  • 16.11. Karl Storz SE & Co. KG
  • 16.12. Ovesco Endoscope AG
  • 16.13. STERIS plc
  • 16.14. Hangzhou AGS MedTech Co., Ltd.
  • 16.15. Medi-Globe GmbH by DCC Healthcare
  • 16.16. Aohua Endoscopy Co., Ltd.
  • 16.17. Anrei Medical (Hangzhou) Co., Ltd.
  • 16.18. Leo Medical Co. Ltd.
  • 16.19. Seikagaku Corporation
  • 16.20. Creo Medical Group plc
  • 16.21. Jiangsu Vedkang Medical Science and Technology Co., Ltd.
  • 16.22. MTW-Endoskopie W. Haag KG
  • 16.23. Cosmo Pharmaceuticals N.V.
  • 16.24. GI Supply, Inc.
  • 16.25. Zeon Medical Co., Ltd.
  • 16.26. Endo-Flex GmbH by Medi-Globe Group
  • 16.27. Lumendi AG
  • 16.28. Upexmed Co., Ltd.
  • 16.29. Actuated Medical, Inc.
  • 16.30. Agilis Robotics Limited
  • 16.31. Ambu A/S
  • 16.32. ATRACT Device & Co.
  • 16.33. Beijing ZKSK Technology Co., Ltd.
  • 16.34. Flexicare Medical Ltd.
  • 16.35. Interscope, Inc.
  • 16.36. Kachu Technology Co., Ltd.
  • 16.37. Neptune Medical Inc.
  • 16.38. Richard Wolf GmbH
  • 16.39. Sunarrow Co., Ltd.
  • 16.40. TOP Corporation
  • 16.41. Zhejiang Soudon Medical Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLONOSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLONOSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLONOSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DUODENOSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUODENOSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DUODENOSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ESD KNIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ESD KNIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ESD KNIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUAL KNIFE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DUAL KNIFE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUAL KNIFE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IT KNIFE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IT KNIFE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IT KNIFE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HOOK KNIFE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HOOK KNIFE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOOK KNIFE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEEDLE KNIFE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEEDLE KNIFE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEEDLE KNIFE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTION NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTION NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTION NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEMOSTASIS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMOSTASIS DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEMOSTASIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COAGULATION FORCEPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COAGULATION FORCEPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COAGULATION FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMOSTATIC FORCEPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMOSTATIC FORCEPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMOSTATIC FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TISSUE RETRACTION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TISSUE RETRACTION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TISSUE RETRACTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACCESSORY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACCESSORY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACCESSORY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAP & HOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAP & HOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAP & HOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSUFFLATIONS UNITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSUFFLATIONS UNITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSUFFLATIONS UNITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TROCARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TROCARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TROCARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FULL-THICKNESS RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FULL-THICKNESS RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FULL-THICKNESS RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HYBRID ESD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYBRID ESD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HYBRID ESD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARTIAL-THICKNESS RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARTIAL-THICKNESS RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARTIAL-THICKNESS RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTRIC CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTRIC CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTRIC CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PRECANCEROUS LESIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECANCEROUS LESIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PRECANCEROUS LESIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BENIGN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BENIGN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BENIGN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALIGNANT TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MALIGNANT TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALIGNANT TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ESD KNIVES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY HEMOSTASIS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ACCESSORY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY MALIGNANT TUMORS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY END-USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 329. ITALY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SIZE, BY ENDOSCOPES, 2018-2032 (USD MILLION)
  • TABLE 330. ITALY ENDOSCOPIC SUBMUCOSAL DISSECTION MARKE